速递｜减重20.1%！礼来新型创新药Eloralintide落地中国临床

Core Viewpoint - Eli Lilly's new long-acting insulin receptor agonist, Eloralintide, has received approval from China's CDE and will initiate three global pivotal Phase III clinical studies, marking a significant advancement in metabolic health [4]. Clinical Research Results and Advantages - Eloralintide has a plasma half-life of approximately 14 days, allowing for weekly subcutaneous injections, enhancing patient convenience [6]. - In Phase II clinical trials, Eloralintide demonstrated a significant dose-dependent weight loss effect, with the highest dose group achieving a weight reduction of 20.1% and an average waist circumference reduction of 17.1 cm, far exceeding the placebo group [6]. - The drug not only aids in weight loss but also improves multiple cardiovascular risk indicators, including blood pressure, blood lipids, and blood glucose, while showing good safety across all dosage groups [6]. - A dose escalation scheme further reduces gastrointestinal discomfort, ensuring patients can continue treatment [6]. Global Phase III Clinical Studies - The three Phase III clinical studies launched in China address the treatment needs of different obesity populations, including studies on obese/overweight patients without type 2 diabetes, obese patients with diabetes, and combination therapy for patients with poor response to incretin drugs [7]. - Eli Lilly's Vice President and General Manager for China stated that the launch of Eloralintide in China is a significant expansion of the company's research footprint in metabolic diseases, aiming for global simultaneous market entry [7]. - The company is building a multi-dimensional obesity treatment solution, incorporating various drug types to meet individual patient needs and drive innovation in obesity treatment [7].